News

VLEVA's EU-subsidiemonitor 2021-2022; I3, het Interregional Innovation Investment Instrument

Published on | 1 year ago

Programmes
EIE

In the 'EU-subsidiemonitor 2021-2022' VLEVA investigates how Flemish organisations participate in European subsidised programs. This time with a focus for Interregional Innovation Investment Instrument - I3

  • I3 finances International cooperations building innovative value chains

  • Discover how Flanders’ FOOD with the HIGHFIVE-project stimulates digital and green growth in the agrofood-value chain in Europe.

  • Get information on the open calls in I3

Deadline for strand 1 and strand 2a are both on december 5th 2024. Recordings of the information sessions can be found here.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1882 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.